Reading ENOV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENOV free→Reading ENOV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENOV free→NYSEHealth CareMedical DevicesSnapshot 2026-06-12
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, which may impact performance compared to sector peers, where it is typical. Peer multiples imply a price about 71% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $21.80. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $22 ENOV trades at 6× p/e, below its 23× p/e peer median. Our $81 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 73% below a flat-multiple fair value, below our forecast of about 7%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -0.21x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the US dollar.
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.90 → $0.85 (-5.9% / 30d). 1 raised, 8 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 92% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$201.
How much price usually moves either way.
On a bad day, this stock has moved -$583.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,124.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This would signal a slowdown in sales growth, raising concerns about market demand.
Confirms:Q2 organic revenue growth is below 4%.
Disproves:Q2 organic revenue growth reported at 4% or higher.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ENOV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, the Company issued a press release reporting financial results for the first quarter ended April 3, 2026. A copy of the Company's press release is attached to this report as Exhibit 99.1 and is incorporated into
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ENOV Enovis | Typical Show detailsSector percentile: 58 of 100 | inexpensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 67 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain the revenue guidance for 2026 between $2.31 billion and $2.37 billion.
Continue to target adjusted EBITDA within the range of $425 million to $435 million for 2026.
Emphasize commercial execution and innovation to drive growth and competitive positioning.
Focus on improving operating income through cost management and revenue growth.
Drive revenue growth through strategic market expansion and product innovation.
Why it matters: Revenue growth reflects market expansion and product innovation. It's vital for the company's future.
Confirms:Q2 revenue rises above $600M. This helps management's growth plans.
Disproves:Q2 revenue stays below $580M, suggesting struggles in market expansion.
Why it matters: Higher gross profit means better efficiency. This is key for long-term success.
Confirms:Q2 gross profit rises above $370M, indicating better cost control.
Disproves:Q2 gross profit drops below $360M. This shows ongoing operational issues.
Why it matters: Improving operating income shows progress in cost management. This is key for future growth.
Confirms:Q2 operating income goes above $10M. This shows good cost control.
Disproves:Q2 operating income stays below $6M. This shows ongoing cost problems.
Approval of an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan.